SR-8278 is an experimental drug that was developed as an antagonist of Rev-ErbAα.

[1] It has been used to demonstrate potential applications of Rev-ErbAα antagonists in the treatment of conditions such as Duchenne muscular dystrophy and Alzheimer's disease.

[2][3] This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.